19Labs kit remotely monitors quarantined coronavirus patients
March 11, 2020
California-based 19Labs has introduced a smart monitoring kit to increase the time patients can spend in at-home quarantine while being evaluated for possible coronavirus and other infections.
The Gale QKit allows municipalities and governments to monitor patients' health at home safely using smart diagnostic devices, increasing the period during which individuals can remain at home.
Based on the firm’s Gale Mini telehealth product, the kit enables governments and municipalities to implement minimally disruptive quarantine policies by enabling effective monitoring of potentially infected individuals at home.
"Doctor Nancy Messonnier, director of CDC's National Center for Immunization & Respiratory Diseases, urged hospitals to explore expanding telehealth services," said Ram Fish, CEO of 19Labs. “The Gale QKit allows hospitals to quickly follow suit, and expand their telehealth offering to address quarantine's special needs.”
The kit is tailored for viral respiratory infections such as Covid-19. It allows clinicians to monitor patients' health using clinical diagnostic devices such as the EKO digital stethoscope, pulse oximetry and an infra-red thermometer, all integrated through 19Labs' cloud-based HIPAA-compliant platform.
The diagnostic devices are FDA approved, and easy to use, providing critical information to the clinicians in real time. Gale's open architecture allows users to address future epidemics by integrating other third-party diagnostic devices and test kits.
By communicating via Zoom video conferencing, local authorities can leverage either their own community clinical teams or clinical teams from across the country. Local health authorities can educate patients through interactive guides, videos, webinars and curated live web content, making the latest government and healthcare guidelines instantly and easily accessible.
The Gale platform can be quickly deployed as it does not require any IT integration efforts. It is HIPAA compliant and no health data are retained by 19Labs. The connection between patients and clinicians is encrypted, secure and private. It leverages off-the-shelf Samsung tablets, Android Enterprise and mobile technologies.
"As the number of infected persons grows, healthcare officials face increasingly difficult choices – either hospitalising patients with minor symptoms or allowing those individuals to stay at home away from clinical care,” said Fish. “Smart, affordable telehealth minimises the need to transport patients back and forth to the hospital or to send healthcare workers to the patient's home. Gale QKit is safe yet effective and lessens the burden on providers and hospitals while minimising the risk of infection and promoting public health."
The Gale platform from 19Labs is making healthcare accessible with effective, affordable telehealth point-of-care for employers, pharmacies and rural communities. The company's products include Gale Mini, a managed Android Telehealth 2.0 application, and the Gale DMS deployment management cloud platform, allowing care organisations to support, manage and monitor deployments.
The company was founded in 2015 and is led by former Apple, Samsung and Qualcomm executives. The company's investors include TransPacific Ventures, Tec Ventures and Torrey Pines Ventures. It is based in Menlo Park, California, and Victoria, British Columbia.